Hyloris Closes A Dramatic 2024 With A Move Towards Profit

The Firm Reported Increased Revenue Driven By Royalties

After announcing updates in its ongoing legal battle and a leadership shakeup earlier this fiscal year, Hyloris closed 2024 with a slight rise in revenue and a shrinking of its reported net loss.

Belgium map and flag
Belgium updates rules on importing unlicensed products

Hyloris Pharmaceuticals has reported a slight rise in its total revenue as part of its full year results for 2024, marking a close to a particularly tumultuous period for the Belgian value-added medicines specialist that has moved closer to profit.

For the whole of the 2024 financial year, Hyloris reported growth in its total revenue and other operating income to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics Bulletin

Aurobindo Addresses Rumor Of $5bn Zentiva Buyout

 
• By 

Rumours are circulating that Aurobindo could be set to take ownership of Zentiva from current owner Advent in a $5bn transaction, which would represent one of the largest off-patent sector deals in some time.

Alvotech Focuses On Value Over Volume As Sales Continue To Grow

 
• By 

As Alvotech announced first-half results that outpaced expectations, the biosimilars developer’s management explained that the firm was targeting value and product margin over market share and volumes.

Generic Drug Industry Seeks More US FDA Communication Reforms In GDUFA Renewal

 
• By 

Enhancing the consistency and clarity of information requests and discipline review letters, and improving assessment milestone communications are key areas targeted by generic drug makers for user fee program negotiations.

Danish Probe Could Influence Rethink Of Controversial EU Urban Wastewater Rules

 

Some medicines may be subject to price rises that make them unaffordable if the burden of paying for extra wastewater treatment is not more fairly distributed across different industries, the Danish pharmaceutical industry association has warned.

More from Business

Formycon’s Search For Keytruda Biosimilar Partner Is Key To Deliver FY2025 Guidance

 

With H1 revenues not even hitting double-digits, Formycon is bidding on partnerships and royalties to generate at least €46m over the next half-year to reach its revenue goal.

$160m War Chest Readied For Aquestive’s Oral Epinephrine Film Launch

 
• By 

Filed through the FDA’s 505(b)(2) hybrid new drug application pathway, Aquestive Therapeutics’ proposed Anaphylm (epinephrine) sublingual film has received major financial backing with a pair of funding deals.

Byooviz US Launch Slated For 2026 As Harrow Touts Immediate Uptake Potential

 
• By 

Harrow is taking aim at launching new partner Samsung Bioepis’ Byooviz biosimilar to Lucentis in 2026.